Reversal of iron‐induced dilated cardiomyopathy during therapy with deferasirox in beta‐thalassemia | Zendy

Trad Omar | Zendy; Hamdan Mohamed A. | Zendy; Jamil Altaf | Zendy; Khanani Muhammad F. | Zendy; Ishaqi M. Kashif | Zendy; Shamsi Aisha | Zendy; Hayek Mohamed | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Reversal of iron‐induced dilated cardiomyopathy during therapy with deferasirox in beta‐thalassemia

Author(s) -

Trad Omar,

Hamdan Mohamed A.,

Jamil Altaf,

Khanani Muhammad F.,

Ishaqi M. Kashif,

Shamsi Aisha,

Hayek Mohamed

Publication year - 2009

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.21795

Subject(s) - deferasirox , medicine , ejection fraction , dilated cardiomyopathy , ventricle , deferoxamine , cardiomyopathy , cardiology , thalassemia , beta thalassemia , deferiprone , heart failure

A 15‐year‐old male with β‐thalassemia major developed dilated cardiomyopathy secondary to iron‐overload ( Z ‐scores of left ventricle (LV) dimensions >3, ejection fraction (EF) 33%). Treatment with deferoxamine was unsuccessful, presumably due to poor compliance. After 15 months of using deferasirox (DFX), LV end‐diastolic dimension normalized ( Z ‐scores <2), and EF improved to 58%. We conclude that treatment with DFX resulted in a reversal of iron‐induced cardiomyopathy. Pediatr Blood Cancer 2009;52:426–428. © 2008 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research